Eli Lilly and Company logo. (PRNewsfoto/Eli Lilly and Company)
INDIANAPOLIS, March 3, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA). Both doses of baricitinib met the primary efficacy endpoint at Week 36, demonstrating a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo. AA is an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress. Baricitinib has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of AA. This classification aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may dem
A New Frontier to Fight This Hair-Loss Disease
Copy link
Caption
Alopecia areata, an autoimmune disease in which patients lose hair in random patches, impacts 2 percent of people globally, yet there are no FDA-approved treatments. But promising options are emerging.
By Ian Graber-Stiehl
Copy link
WHY YOU SHOULD CARE
Because this disease affects 2 percent of people globally and might be on the verge of its first effective treatment.
By Ian Graber-Stiehl
Alopecia areata, an autoimmune disease in which patients lose hair in random patches, impacts 2 percent of people globally, yet there are no FDA-approved treatments. People with the condition are also more prone to depression.